Paper42972012PubMed
The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma.
Farag OB and 25 others. Leukemia, 2026.
Cite this record
ConductScience Library. The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma. Papers, record 42972012. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42972012
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma.
- Journal
- Leukemia
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-11-02
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants32
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01CA296318 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | R01CA296318 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| R01CA296318 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | R01CA296318 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| R01CA296318 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | R01CA296318 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| R01CA296318 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | R01CA296318 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| R01CA296318 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | R01CA296318 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| R01CA296318 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | R01CA296318 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER | |
| P30CA240139 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P30CA240139 | PubMed | NIH RePORTER |
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41233615 | FDA approves 100th small-molecule kinase inhibitor. | Nat Rev Drug Discov | 2025 | https://conductscience.org/library/papers/41233615 | PubMed |
| 2 | 31819260 | The functional landscape of the human phosphoproteome. | Nat Biotechnol | 2020 | https://conductscience.org/library/papers/31819260 | PubMed |
| 3 | 30445427 | 15 years of PhosphoSitePlus®: integrating post-translationally modified sites, disease variants and isoforms. | Nucleic Acids Res | 2019 | https://conductscience.org/library/papers/30445427 | PubMed |
| 4 | 36631611 | An atlas of substrate specificities for the human serine/threonine kinome. | Nature | 2023 | https://conductscience.org/library/papers/36631611 | PubMed |
| 5 | 38720073 | The intrinsic substrate specificity of the human tyrosine kinome. | Nature | 2024 | https://conductscience.org/library/papers/38720073 | PubMed |
| 6 | 27618563 | 2016 US lymphoid malignancy statistics by World Health Organization subtypes. | CA Cancer J Clin | 2016 | https://conductscience.org/library/papers/27618563 | PubMed |
| 7 | 10676951 | Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. | Nature | 2000 | https://conductscience.org/library/papers/10676951 | PubMed |
| 8 | 19038878 | Stromal gene signatures in large-B-cell lymphomas. | N Engl J Med | 2008 | https://conductscience.org/library/papers/19038878 | PubMed |
| 9 | 32289277 | A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. | Cancer Cell | 2020 | https://conductscience.org/library/papers/32289277 | PubMed |
| 10 | 26314773 | Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2015 | https://conductscience.org/library/papers/26314773 | PubMed |
| 11 | 40991874 | Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/40991874 | PubMed |
| 12 | 33657296 | Diffuse Large B-Cell Lymphoma. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33657296 | PubMed |
| 13 | 35933930 | Treatment strategies for patients with diffuse large B-cell lymphoma. | Cancer Treat Rev | 2022 | https://conductscience.org/library/papers/35933930 | PubMed |
| 14 | 37879047 | Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). | Blood | 2024 | https://conductscience.org/library/papers/37879047 | PubMed |
| 15 | 30901302 | Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30901302 | PubMed |
| 16 | 38899693 | Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. | N Engl J Med | 2024 | https://conductscience.org/library/papers/38899693 | PubMed |
| 17 | 23813874 | Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. | Am J Hematol | 2013 | https://conductscience.org/library/papers/23813874 | PubMed |
| 18 | 16895969 | Recruitment dynamics of GAK and auxilin to clathrin-coated pits during endocytosis. | J Cell Sci | 2006 | https://conductscience.org/library/papers/16895969 | PubMed |
| 19 | 19654208 | GAK, a regulator of clathrin-mediated membrane traffic, also controls centrosome integrity and chromosome congression. | J Cell Sci | 2009 | https://conductscience.org/library/papers/19654208 | PubMed |
| 20 | 31962345 | Dynamics of Auxilin 1 and GAK in clathrin-mediated traffic. | J Cell Biol | 2020 | https://conductscience.org/library/papers/31962345 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42972012
GET https://conductscience.org/api/papers/v1/42972012/authors?page=2